Trial Profile
Longterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Elivaldogene autotemcel (Primary)
- Indications Adrenoleucodystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors bluebird bio
- 05 Feb 2024 Planned End Date changed from 1 May 2037 to 1 Aug 2038.
- 05 Feb 2024 Planned primary completion date changed from 1 May 2037 to 1 Aug 2038.
- 07 Sep 2023 Status changed from recruiting to active, no longer recruiting.